Levetiracetam Tablet, Film Coated
Product Images NDC 63629-8315

9 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-8315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetamtabletsstructure (Levetiracetamtabletsstructure)

Levetiracetamtabletsstructure (Levetiracetamtabletsstructure)
Chemical structure of Levetiracetam showing a pyrrolidone ring attached to an ethyl group and an amide functional group.*
FDA Label Image

Levetiracetamtabletsfigure1 (Levetiracetamtabletsfigure1)

Levetiracetamtabletsfigure1 (Levetiracetamtabletsfigure1)
A bar chart comparing the percentage of patients among three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). The vertical axis is labeled '% of Patients.' The chart highlights differences in patient percentages across the treatment groups.*
FDA Label Image

Levetiracetamtabletsfigure2 (Levetiracetamtabletsfigure2)

Levetiracetamtabletsfigure2 (Levetiracetamtabletsfigure2)
A bar chart showing the percentage of patients experiencing an outcome across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with the placebo group at 6.3%, the 1000 mg/day Levetiracetam group at 20.8%, and the 2000 mg/day Levetiracetam group at 35.2%.*
FDA Label Image

Levetiracetamtabletsfigure3 (Levetiracetamtabletsfigure3)

Levetiracetamtabletsfigure3 (Levetiracetamtabletsfigure3)
A bar graph comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The y-axis shows the percentage of patients from 0% to 45%, with the placebo group at 14.4% and the Levetiracetam 3000 mg/day group at 39.4%. The placebo group includes 104 patients; the Levetiracetam group includes 180 patients.*
FDA Label Image

Levetiracetamtabletsfigure4 (Levetiracetamtabletsfigure4)

Levetiracetamtabletsfigure4 (Levetiracetamtabletsfigure4)
A bar chart comparing the percentage of patients between a placebo group (97 patients) and a Levetiracetam group (101 patients). The chart shows approximately 19.6% of patients in the placebo group and 44.6% in the Levetiracetam group, with an asterisk above the Levetiracetam bar indicating statistical significance.*
FDA Label Image

Levetiracetamtabletsfigure5 (Levetiracetamtabletsfigure5)

Levetiracetamtabletsfigure5 (Levetiracetamtabletsfigure5)
A bar chart comparing the percentage of patients in two groups: Placebo (N=51) and Levetiracetam (N=58). The Placebo group shows about 19.6% of patients, while the Levetiracetam group shows about 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*
FDA Label Image

Levetiracetamtabletsfigure6 (Levetiracetamtabletsfigure6)

Levetiracetamtabletsfigure6 (Levetiracetamtabletsfigure6)
A bar chart comparing the percentage of patients between placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients from 0% to 100%. The placebo group shows 45.2%, and the Levetiracetam group shows 72.2%, indicating a higher percentage in the Levetiracetam group.*
FDA Label Image
FDA Label Image

Label (Lbl636298315)

Label (Lbl636298315)
Levetiracetam 750 mg film-coated tablet label by Bryant Ranch Prepack. The label includes storage instructions (20°-25°C), a warning to keep out of reach of children, and references Keppra 750 mg tablets by Annora Pharma Pvt. Ltd. It displays NDC 63629-8315 and package quantity of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.